These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

419 related articles for article (PubMed ID: 33395057)

  • 1. Angiotensin Converting Enzyme Inhibitors and Angiotensin Receptor Blockers and the Risk of SARS-CoV-2 Infection or Hospitalization With COVID-19 Disease: A Systematic Review and Meta-Analysis.
    Tleyjeh IM; Bin Abdulhak AA; Tlayjeh H; Al-Mallah MH; Sohail MR; Hassett LC; Siller-Matula JM; Kashour T
    Am J Ther; 2020 Dec; 29(1):e74-e84. PubMed ID: 33395057
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Angiotensin Converting Enzyme Inhibitors and Angiotensin Receptor Blockers and Mortality Among COVID-19 Patients: A Systematic Review and Meta-Analysis.
    Kashour T; Bin Abdulhak AA; Tlayjeh H; Hassett LC; Noman A; Mohsen A; Al-Mallah MH; Tleyjeh IM
    Am J Ther; 2023 Jul-Aug 01; 30(4):e336-e346. PubMed ID: 33201001
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Risks and Impact of Angiotensin-Converting Enzyme Inhibitors or Angiotensin-Receptor Blockers on SARS-CoV-2 Infection in Adults: A Living Systematic Review.
    Mackey K; King VJ; Gurley S; Kiefer M; Liederbauer E; Vela K; Sonnen P; Kansagara D
    Ann Intern Med; 2020 Aug; 173(3):195-203. PubMed ID: 32422062
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A systematic review and meta-analysis of the use of renin-angiotensin system drugs and COVID-19 clinical outcomes: What is the evidence so far?
    Kurdi A; Abutheraa N; Akil L; Godman B
    Pharmacol Res Perspect; 2020 Dec; 8(6):e00666. PubMed ID: 33084232
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Association Between Renin-Angiotensin-Aldosterone System Inhibitors and Clinical Outcomes in Patients With COVID-19: A Systematic Review and Meta-analysis.
    Baral R; Tsampasian V; Debski M; Moran B; Garg P; Clark A; Vassiliou VS
    JAMA Netw Open; 2021 Mar; 4(3):e213594. PubMed ID: 33787911
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The divergent protective effects of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers on clinical outcomes of coronavirus disease 2019 (COVID-19): a systematic review and meta-analysis.
    Xie Q; Tang S; Li Y
    Ann Palliat Med; 2022 Apr; 11(4):1253-1263. PubMed ID: 34775774
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A systematic review and meta-analysis to evaluate the clinical outcomes in COVID-19 patients on angiotensin-converting enzyme inhibitors or angiotensin receptor blockers.
    Grover A; Oberoi M
    Eur Heart J Cardiovasc Pharmacother; 2021 Mar; 7(2):148-157. PubMed ID: 32542337
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Does taking an angiotensin inhibitor increase the risk for COVID-19? - a systematic review and meta-analysis.
    Ma Z; Wang MP; Liu L; Yu S; Wu TR; Zhao L; Zhang YP; Liang HF; Yang XC
    Aging (Albany NY); 2021 Apr; 13(8):10853-10865. PubMed ID: 33886504
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers on in-hospital mortality among patients with COVID-19: a systematic review and meta-analysis.
    Cai XJ; Tay JCK; Kui SL; Tin AS; Tan VH
    Singapore Med J; 2021 Nov; 62(11):563-567. PubMed ID: 33256355
    [TBL] [Abstract][Full Text] [Related]  

  • 10. SARS-CoV-2 and the Angiotensin-Converting Enzyme 2 Receptor: Angiotensin-Converting Enzyme Inhibitor/Angiotensin 2 Receptor Blocker Utilization and a Shift Towards the Renin-Angiotensin-Aldosterone System Classical Pathway.
    Felber R; New W; Riskin SI
    Cureus; 2024 Mar; 16(3):e55563. PubMed ID: 38576704
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Renin-angiotensin system blockers, risk of SARS-CoV-2 infection and outcomes from CoViD-19: systematic review and meta-analysis.
    Lee MMY; Docherty KF; Sattar N; Mehta N; Kalra A; Nowacki AS; Solomon SD; Vaduganathan M; Petrie MC; Jhund PS; McMurray JJV
    Eur Heart J Cardiovasc Pharmacother; 2022 Feb; 8(2):165-178. PubMed ID: 33337478
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Associations Between the Use of Renin-Angiotensin System Inhibitors and the Risks of Severe COVID-19 and Mortality in COVID-19 Patients With Hypertension: A Meta-Analysis of Observational Studies.
    Dai XC; An ZY; Wang ZY; Wang ZZ; Wang YR
    Front Cardiovasc Med; 2021; 8():609857. PubMed ID: 33981731
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association of angiotensin-converting enzyme inhibitors and angiotensin-receptor blockers with risk of mortality, severity or SARS-CoV-2 test positivity in COVID-19 patients: meta-analysis.
    Biswas M; Kali MSK
    Sci Rep; 2021 Mar; 11(1):5012. PubMed ID: 33658619
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Influence of angiotensin converting enzyme inhibitors/angiotensin receptor blockers on the risk of all-cause mortality and other clinical outcomes in patients with confirmed COVID-19: A systemic review and meta-analysis.
    Jia N; Zhang G; Sun X; Wang Y; Zhao S; Chi W; Dong S; Xia J; Zeng P; Liu D
    J Clin Hypertens (Greenwich); 2021 Sep; 23(9):1651-1663. PubMed ID: 34320275
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Renin-Angiotensin-Aldosterone System Inhibitors and Risks of Severe Acute Respiratory Syndrome Coronavirus 2 Infection: A Systematic Review and Meta-Analysis.
    Chan CK; Huang YS; Liao HW; Tsai IJ; Sun CY; Pan HC; Chueh JS; Wang JT; Wu VC; Chu TS;
    Hypertension; 2020 Nov; 76(5):1563-1571. PubMed ID: 32869673
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Retrospective Study from 2 Centers in China on the Effects of Continued Use of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers in Patients with Hypertension and COVID-19.
    Wang Z; Zhang D; Wang S; Jin Y; Huan J; Wu Y; Xia C; Li Z; Qi X; Zhang D; Han X; Zhu X; Qu Y; Wang Q
    Med Sci Monit; 2020 Sep; 26():e926651. PubMed ID: 32969367
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Renin-Angiotensin System Blockers and the Risk of COVID-19-Related Mortality in Patients with Kidney Failure.
    Soler MJ; Noordzij M; Abramowicz D; de Arriba G; Basile C; van Buren M; Covic A; Crespo M; Duivenvoorden R; Massy ZA; Ortiz A; Sanchez JE; Petridou E; Stevens K; White C; Vart P; Gansevoort RT;
    Clin J Am Soc Nephrol; 2021 Jul; 16(7):1061-1072. PubMed ID: 34088718
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Renin-Angiotensin System Inhibitors and COVID-19: a Systematic Review and Meta-Analysis. Evidence for Significant Geographical Disparities.
    Patoulias D; Katsimardou A; Stavropoulos K; Imprialos K; Kalogirou MS; Doumas M
    Curr Hypertens Rep; 2020 Sep; 22(11):90. PubMed ID: 32910274
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of renin-angiotensin-aldosterone system inhibitors on disease severity and mortality in patients with COVID-19: A meta-analysis.
    Zhang G; Wu Y; Xu R; Du X
    J Med Virol; 2021 Apr; 93(4):2287-2300. PubMed ID: 33231299
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Association of Use of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers With Testing Positive for Coronavirus Disease 2019 (COVID-19).
    Mehta N; Kalra A; Nowacki AS; Anjewierden S; Han Z; Bhat P; Carmona-Rubio AE; Jacob M; Procop GW; Harrington S; Milinovich A; Svensson LG; Jehi L; Young JB; Chung MK
    JAMA Cardiol; 2020 Sep; 5(9):1020-1026. PubMed ID: 32936273
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.